LDN-212854 - CAS 1432597-26-6
LDN-212854 is a novel BMP inhibitor that exhibits substantially greater selectivity for BMP versus the TGF-β type I receptors; possesses a bias towards ALK2(IC50=1.3 nM) versus ALK1 and ALK3 compared to other inhibitors.
IC50 value: 1.3 nM 
In vitro, LDN-212854 exhibits some selectivity for ALK2 in preference to other BMP type I receptors, ALK1 and ALK3, which may permit the interrogation of ALK2-mediated signaling, transcriptional activity and function. LDN-212854 potently inhibits
heterotopic ossification in an inducible transgenic mutant ALK2 mouse model of fibrodysplasia ossificans progressiva.
* For research use only. Not for human or veterinary use.
|Solubility||DMSO: ≥ 30 mg/mL|
|Storage||Store at -20°C|
|IC50||1.3 nM |